Diagnostics Pipeline: Cizzle Bio Introduces Test for Earlier Lung Cancer Detection
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
Research team creates a promising new mass spectrometry-based blood lipid test.
This potential game changer may revolutionize the kind of home test women who miss a period use to determine if they are pregnant.